 Charles Daley
Concepts (430)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 75 | 2022 | 279 | 15.610 |
Why?
| | Mycobacterium avium Complex | 36 | 2022 | 87 | 7.200 |
Why?
| | Mycobacterium abscessus | 27 | 2022 | 79 | 6.950 |
Why?
| | Mycobacterium avium-intracellulare Infection | 23 | 2022 | 60 | 6.920 |
Why?
| | Antitubercular Agents | 37 | 2021 | 165 | 6.570 |
Why?
| | Tuberculosis | 31 | 2021 | 246 | 6.080 |
Why?
| | Lung Diseases | 37 | 2022 | 725 | 6.070 |
Why?
| | Nontuberculous Mycobacteria | 41 | 2022 | 161 | 5.800 |
Why?
| | Tuberculosis, Pulmonary | 25 | 2021 | 127 | 5.290 |
Why?
| | Anti-Bacterial Agents | 49 | 2022 | 1366 | 4.930 |
Why?
| | Tuberculosis, Multidrug-Resistant | 12 | 2019 | 45 | 4.150 |
Why?
| | Mycobacterium Infections | 12 | 2019 | 64 | 4.040 |
Why?
| | Mycobacterium kansasii | 10 | 2020 | 15 | 3.700 |
Why?
| | Mycobacterium tuberculosis | 26 | 2019 | 281 | 3.350 |
Why?
| | Mycobacterium | 13 | 2019 | 91 | 3.000 |
Why?
| | Bronchiectasis | 15 | 2020 | 96 | 2.660 |
Why?
| | Amikacin | 12 | 2021 | 17 | 2.640 |
Why?
| | Macrolides | 14 | 2021 | 63 | 2.640 |
Why?
| | Cystic Fibrosis | 16 | 2022 | 913 | 2.430 |
Why?
| | Interferon-gamma Release Tests | 6 | 2016 | 27 | 2.300 |
Why?
| | Drug Resistance, Bacterial | 19 | 2021 | 154 | 2.160 |
Why?
| | Sputum | 25 | 2020 | 287 | 1.950 |
Why?
| | Latent Tuberculosis | 8 | 2017 | 65 | 1.560 |
Why?
| | Pneumonia, Bacterial | 6 | 2017 | 104 | 1.530 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2016 | 119 | 1.440 |
Why?
| | Clofazimine | 4 | 2021 | 15 | 1.370 |
Why?
| | Antibiotics, Antitubercular | 9 | 2021 | 37 | 1.370 |
Why?
| | Humans | 168 | 2022 | 114571 | 1.310 |
Why?
| | Rifampin | 13 | 2021 | 74 | 1.280 |
Why?
| | Pneumonia | 4 | 2021 | 559 | 1.120 |
Why?
| | Clarithromycin | 12 | 2021 | 29 | 1.100 |
Why?
| | HIV Infections | 15 | 2022 | 2498 | 1.080 |
Why?
| | Oxazolidinones | 3 | 2013 | 14 | 1.070 |
Why?
| | Acetamides | 3 | 2013 | 30 | 1.060 |
Why?
| | Global Health | 8 | 2018 | 346 | 1.020 |
Why?
| | Ethambutol | 10 | 2021 | 21 | 1.010 |
Why?
| | Disease Outbreaks | 5 | 2019 | 291 | 0.940 |
Why?
| | Tuberculin Test | 6 | 2016 | 35 | 0.930 |
Why?
| | Microbial Sensitivity Tests | 17 | 2021 | 296 | 0.910 |
Why?
| | Equipment Contamination | 2 | 2019 | 51 | 0.900 |
Why?
| | Drug Therapy, Combination | 18 | 2021 | 1004 | 0.890 |
Why?
| | Aged | 52 | 2021 | 20218 | 0.860 |
Why?
| | Professional Practice Gaps | 1 | 2020 | 10 | 0.850 |
Why?
| | Middle Aged | 59 | 2021 | 28854 | 0.770 |
Why?
| | Treatment Outcome | 29 | 2020 | 9190 | 0.760 |
Why?
| | Disease Management | 4 | 2021 | 605 | 0.750 |
Why?
| | San Francisco | 10 | 2014 | 49 | 0.730 |
Why?
| | Molecular Epidemiology | 4 | 2006 | 58 | 0.710 |
Why?
| | Male | 74 | 2022 | 60817 | 0.650 |
Why?
| | Female | 73 | 2021 | 63070 | 0.640 |
Why?
| | Adult | 48 | 2022 | 32077 | 0.640 |
Why?
| | Health Care Sector | 2 | 2013 | 32 | 0.620 |
Why?
| | Extensively Drug-Resistant Tuberculosis | 2 | 2013 | 6 | 0.620 |
Why?
| | Retrospective Studies | 28 | 2022 | 11642 | 0.610 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2019 | 64 | 0.610 |
Why?
| | Phylogeny | 5 | 2021 | 730 | 0.600 |
Why?
| | Azithromycin | 6 | 2021 | 84 | 0.600 |
Why?
| | Genome, Bacterial | 5 | 2021 | 103 | 0.580 |
Why?
| | Linezolid | 4 | 2018 | 15 | 0.560 |
Why?
| | Lung | 14 | 2022 | 3558 | 0.540 |
Why?
| | United States | 29 | 2021 | 12551 | 0.520 |
Why?
| | Communicable Disease Control | 1 | 2014 | 69 | 0.500 |
Why?
| | Sex Factors | 1 | 2019 | 1971 | 0.490 |
Why?
| | Serologic Tests | 1 | 2012 | 58 | 0.480 |
Why?
| | Professional Practice | 1 | 2012 | 67 | 0.470 |
Why?
| | Rifabutin | 2 | 2012 | 6 | 0.450 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 91 | 0.450 |
Why?
| | Opportunistic Infections | 1 | 2011 | 53 | 0.450 |
Why?
| | Practice Guidelines as Topic | 6 | 2015 | 1541 | 0.440 |
Why?
| | Pyrazinamide | 4 | 2021 | 11 | 0.440 |
Why?
| | Occupational Health | 1 | 2013 | 211 | 0.410 |
Why?
| | Recurrence | 10 | 2019 | 988 | 0.400 |
Why?
| | Mass Screening | 3 | 2016 | 1066 | 0.400 |
Why?
| | Occupational Exposure | 1 | 2013 | 312 | 0.390 |
Why?
| | Cardiac Surgical Procedures | 3 | 2019 | 474 | 0.390 |
Why?
| | Administration, Inhalation | 6 | 2021 | 667 | 0.380 |
Why?
| | Aged, 80 and over | 14 | 2021 | 6818 | 0.370 |
Why?
| | Incidence | 10 | 2019 | 2454 | 0.370 |
Why?
| | Health Personnel | 3 | 2014 | 515 | 0.340 |
Why?
| | Antigens, Bacterial | 5 | 2012 | 129 | 0.340 |
Why?
| | Directly Observed Therapy | 2 | 2005 | 14 | 0.340 |
Why?
| | Drug Administration Schedule | 7 | 2020 | 808 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 555 | 0.330 |
Why?
| | Organ Transplantation | 1 | 2009 | 160 | 0.330 |
Why?
| | Tuberculosis, Pleural | 2 | 2003 | 6 | 0.330 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2379 | 0.320 |
Why?
| | Morbidity | 2 | 2019 | 268 | 0.320 |
Why?
| | Genomics | 4 | 2021 | 514 | 0.310 |
Why?
| | Diarylquinolines | 2 | 2019 | 7 | 0.300 |
Why?
| | ROC Curve | 4 | 2020 | 489 | 0.290 |
Why?
| | World Health Organization | 2 | 2018 | 114 | 0.290 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1294 | 0.290 |
Why?
| | Disease Progression | 6 | 2020 | 2486 | 0.290 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 91 | 0.290 |
Why?
| | Mutation | 5 | 2019 | 3378 | 0.280 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 64 | 0.280 |
Why?
| | Water Microbiology | 1 | 2005 | 75 | 0.270 |
Why?
| | Drug Synergism | 3 | 2021 | 360 | 0.270 |
Why?
| | DNA Fingerprinting | 1 | 2004 | 25 | 0.270 |
Why?
| | Risk Factors | 9 | 2019 | 9078 | 0.270 |
Why?
| | Contact Tracing | 1 | 2004 | 27 | 0.270 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2005 | 78 | 0.270 |
Why?
| | DNA, Bacterial | 3 | 2021 | 300 | 0.260 |
Why?
| | Self Administration | 1 | 2004 | 130 | 0.260 |
Why?
| | Biomedical Research | 5 | 2020 | 585 | 0.260 |
Why?
| | Biomarkers | 3 | 2020 | 3485 | 0.260 |
Why?
| | Prospective Studies | 13 | 2021 | 6288 | 0.260 |
Why?
| | Research | 2 | 2018 | 464 | 0.250 |
Why?
| | Pneumonectomy | 2 | 2016 | 125 | 0.250 |
Why?
| | Republic of Korea | 6 | 2019 | 26 | 0.240 |
Why?
| | Registries | 5 | 2020 | 1915 | 0.240 |
Why?
| | Adolescent | 17 | 2021 | 18658 | 0.240 |
Why?
| | Isoniazid | 4 | 2019 | 51 | 0.230 |
Why?
| | Administration, Oral | 3 | 2020 | 796 | 0.230 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2191 | 0.230 |
Why?
| | Spectinomycin | 1 | 2021 | 3 | 0.230 |
Why?
| | Thorax | 1 | 2022 | 47 | 0.230 |
Why?
| | Radiography, Thoracic | 3 | 2017 | 179 | 0.220 |
Why?
| | Cohort Studies | 8 | 2020 | 5000 | 0.220 |
Why?
| | Bacteriophages | 1 | 2022 | 62 | 0.220 |
Why?
| | Comorbidity | 4 | 2019 | 1645 | 0.210 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 5 | 0.210 |
Why?
| | Oxazepines | 1 | 2020 | 4 | 0.210 |
Why?
| | Peptidyl Transferases | 1 | 2020 | 5 | 0.210 |
Why?
| | Serine Proteases | 1 | 2020 | 16 | 0.210 |
Why?
| | Safety | 1 | 2003 | 327 | 0.210 |
Why?
| | Benzoxazoles | 1 | 2020 | 23 | 0.210 |
Why?
| | Respiratory Therapy | 1 | 2020 | 18 | 0.210 |
Why?
| | Cluster Analysis | 4 | 2020 | 467 | 0.210 |
Why?
| | Time Factors | 7 | 2020 | 7029 | 0.210 |
Why?
| | Prevalence | 4 | 2019 | 2393 | 0.210 |
Why?
| | Young Adult | 10 | 2019 | 10987 | 0.210 |
Why?
| | Nitroimidazoles | 1 | 2019 | 6 | 0.200 |
Why?
| | Imipenem | 4 | 2021 | 16 | 0.200 |
Why?
| | Mycobacterium fortuitum | 1 | 2019 | 2 | 0.200 |
Why?
| | Area Under Curve | 3 | 2020 | 319 | 0.200 |
Why?
| | Oxazoles | 1 | 2019 | 31 | 0.190 |
Why?
| | Durable Medical Equipment | 1 | 2019 | 3 | 0.190 |
Why?
| | Genotyping Techniques | 1 | 2019 | 73 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4950 | 0.190 |
Why?
| | Cost of Illness | 1 | 2021 | 296 | 0.190 |
Why?
| | Anti-HIV Agents | 3 | 2016 | 688 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 230 | 0.180 |
Why?
| | DNA Gyrase | 1 | 2018 | 12 | 0.180 |
Why?
| | Patient Selection | 1 | 2003 | 707 | 0.180 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 129 | 0.180 |
Why?
| | Bronchoscopy | 1 | 2020 | 242 | 0.180 |
Why?
| | Aza Compounds | 2 | 2010 | 13 | 0.180 |
Why?
| | Respiratory System Agents | 1 | 2018 | 16 | 0.180 |
Why?
| | Musculoskeletal Diseases | 1 | 2019 | 66 | 0.180 |
Why?
| | Genotype | 6 | 2019 | 1848 | 0.180 |
Why?
| | Internationality | 1 | 2019 | 155 | 0.180 |
Why?
| | Treatment Failure | 3 | 2019 | 334 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 2187 | 0.170 |
Why?
| | Tuberculosis Vaccines | 2 | 2010 | 8 | 0.170 |
Why?
| | Quality of Life | 3 | 2018 | 2230 | 0.170 |
Why?
| | Patient Compliance | 3 | 2011 | 609 | 0.170 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 64 | 0.170 |
Why?
| | Liposomes | 1 | 2018 | 169 | 0.170 |
Why?
| | Elephants | 1 | 2017 | 3 | 0.170 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2018 | 77 | 0.170 |
Why?
| | Salvage Therapy | 1 | 2018 | 139 | 0.170 |
Why?
| | Forced Expiratory Volume | 5 | 2020 | 550 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2018 | 171 | 0.170 |
Why?
| | Agammaglobulinemia | 1 | 2017 | 33 | 0.170 |
Why?
| | Fluoroquinolones | 3 | 2018 | 42 | 0.160 |
Why?
| | Quinolines | 2 | 2010 | 140 | 0.160 |
Why?
| | Pulmonary Medicine | 1 | 2018 | 84 | 0.160 |
Why?
| | Kartagener Syndrome | 1 | 2016 | 23 | 0.160 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 323 | 0.160 |
Why?
| | Surgical Equipment | 1 | 2016 | 13 | 0.160 |
Why?
| | Child | 10 | 2021 | 17859 | 0.160 |
Why?
| | Interferon-gamma | 4 | 2007 | 771 | 0.160 |
Why?
| | Prognosis | 5 | 2020 | 3546 | 0.160 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 1920 | 0.150 |
Why?
| | Levofloxacin | 1 | 2016 | 24 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 225 | 0.150 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 82 | 0.150 |
Why?
| | Genes, Bacterial | 1 | 2016 | 162 | 0.150 |
Why?
| | Public Health | 4 | 2016 | 442 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 510 | 0.150 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1561 | 0.140 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 121 | 0.140 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 1004 | 0.140 |
Why?
| | Computational Biology | 1 | 2018 | 473 | 0.140 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2555 | 0.140 |
Why?
| | DNA Transposable Elements | 2 | 2006 | 83 | 0.140 |
Why?
| | Drug Tolerance | 1 | 2015 | 152 | 0.140 |
Why?
| | Cross Infection | 1 | 2016 | 203 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2016 | 291 | 0.130 |
Why?
| | Sequence Analysis, DNA | 2 | 2014 | 734 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 671 | 0.130 |
Why?
| | Genetic Variation | 2 | 2021 | 824 | 0.130 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2007 | 277 | 0.130 |
Why?
| | CD4 Lymphocyte Count | 2 | 2004 | 290 | 0.130 |
Why?
| | MicroRNAs | 1 | 2020 | 604 | 0.130 |
Why?
| | Transcriptome | 2 | 2015 | 676 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 461 | 0.120 |
Why?
| | Societies, Medical | 4 | 2020 | 764 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1159 | 0.120 |
Why?
| | Patient-Centered Care | 1 | 2018 | 485 | 0.120 |
Why?
| | Contraindications | 1 | 2012 | 96 | 0.120 |
Why?
| | Colorado | 4 | 2022 | 4488 | 0.120 |
Why?
| | Glycolipids | 1 | 2012 | 41 | 0.120 |
Why?
| | Consensus | 3 | 2022 | 458 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2015 | 298 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2017 | 550 | 0.120 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 224 | 0.120 |
Why?
| | Models, Statistical | 1 | 2016 | 669 | 0.110 |
Why?
| | Antibodies, Bacterial | 1 | 2012 | 134 | 0.110 |
Why?
| | Immunoglobulin A | 1 | 2012 | 149 | 0.110 |
Why?
| | Drug Resistance, Multiple | 1 | 2011 | 19 | 0.110 |
Why?
| | Cytokines | 2 | 2011 | 1964 | 0.110 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2003 | 138 | 0.110 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 290 | 0.110 |
Why?
| | Debridement | 1 | 2011 | 90 | 0.110 |
Why?
| | Metagenomics | 2 | 2021 | 114 | 0.110 |
Why?
| | Drug Interactions | 1 | 2012 | 402 | 0.110 |
Why?
| | Virulence | 1 | 2011 | 237 | 0.100 |
Why?
| | Hospitals, General | 2 | 2014 | 18 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 899 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2020 | 3249 | 0.100 |
Why?
| | Lung Transplantation | 1 | 2012 | 311 | 0.100 |
Why?
| | Hepatitis, Viral, Human | 1 | 2009 | 27 | 0.100 |
Why?
| | Bacteriological Techniques | 1 | 2009 | 62 | 0.100 |
Why?
| | Netherlands | 2 | 2012 | 73 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 1209 | 0.100 |
Why?
| | Chronic Disease | 2 | 2018 | 1648 | 0.100 |
Why?
| | Forkhead Transcription Factors | 2 | 2007 | 180 | 0.100 |
Why?
| | Hospitalization | 1 | 2018 | 1714 | 0.090 |
Why?
| | Confidence Intervals | 2 | 2015 | 337 | 0.090 |
Why?
| | Cough | 2 | 2020 | 92 | 0.090 |
Why?
| | Interleukins | 2 | 2007 | 237 | 0.090 |
Why?
| | Child, Preschool | 4 | 2016 | 9651 | 0.090 |
Why?
| | Vitamins | 1 | 2010 | 149 | 0.090 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1188 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2009 | 253 | 0.090 |
Why?
| | RNA, Ribosomal, 23S | 2 | 2018 | 13 | 0.090 |
Why?
| | Interleukin-9 | 1 | 2007 | 11 | 0.090 |
Why?
| | Radiography | 2 | 2008 | 850 | 0.090 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2007 | 8 | 0.080 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 44 | 0.080 |
Why?
| | Logistic Models | 3 | 2019 | 2051 | 0.080 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2007 | 35 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2020 | 1681 | 0.080 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 71 | 0.080 |
Why?
| | Survival Analysis | 2 | 2016 | 1410 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 1744 | 0.080 |
Why?
| | Congresses as Topic | 2 | 2020 | 202 | 0.080 |
Why?
| | Th1 Cells | 1 | 2007 | 140 | 0.080 |
Why?
| | Survivors | 1 | 2010 | 405 | 0.080 |
Why?
| | Vitamin D | 1 | 2010 | 347 | 0.080 |
Why?
| | Interleukin-8 | 1 | 2007 | 256 | 0.080 |
Why?
| | Liver Function Tests | 2 | 2003 | 116 | 0.070 |
Why?
| | Coinfection | 2 | 2018 | 114 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 3280 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2005 | 8 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 679 | 0.070 |
Why?
| | Animals | 6 | 2021 | 34687 | 0.070 |
Why?
| | Antirheumatic Agents | 1 | 2007 | 254 | 0.070 |
Why?
| | Europe | 2 | 2016 | 332 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4741 | 0.070 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 191 | 0.070 |
Why?
| | Regression Analysis | 1 | 2008 | 1109 | 0.070 |
Why?
| | Mycobacterium xenopi | 2 | 2014 | 4 | 0.070 |
Why?
| | Streptomycin | 1 | 2003 | 16 | 0.070 |
Why?
| | Respiratory Function Tests | 2 | 2016 | 590 | 0.070 |
Why?
| | Biopsy | 2 | 2005 | 1048 | 0.070 |
Why?
| | Cefoxitin | 2 | 2016 | 10 | 0.070 |
Why?
| | Carrier State | 1 | 2004 | 57 | 0.070 |
Why?
| | Medicare | 2 | 2019 | 664 | 0.070 |
Why?
| | Influenza, Human | 1 | 2009 | 516 | 0.060 |
Why?
| | Pseudomonas Infections | 2 | 2016 | 188 | 0.060 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 379 | 0.060 |
Why?
| | Databases, Factual | 2 | 2019 | 1161 | 0.060 |
Why?
| | Homosexuality, Male | 1 | 2004 | 168 | 0.060 |
Why?
| | Substance Abuse, Intravenous | 1 | 2004 | 115 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 1994 | 0.060 |
Why?
| | Drug Costs | 1 | 2003 | 96 | 0.060 |
Why?
| | Los Angeles | 1 | 2002 | 60 | 0.060 |
Why?
| | Mice | 3 | 2021 | 15429 | 0.060 |
Why?
| | Survival Rate | 1 | 2007 | 1859 | 0.060 |
Why?
| | Peptidoglycan | 1 | 2021 | 25 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2007 | 1242 | 0.060 |
Why?
| | Bacterial Proteins | 1 | 2007 | 770 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 2842 | 0.060 |
Why?
| | Lactams | 1 | 2021 | 38 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2020 | 2926 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 253 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2005 | 461 | 0.050 |
Why?
| | beta-Lactamase Inhibitors | 1 | 2020 | 2 | 0.050 |
Why?
| | Carboxypeptidases | 1 | 2020 | 13 | 0.050 |
Why?
| | Azabicyclo Compounds | 1 | 2020 | 6 | 0.050 |
Why?
| | Cephalosporins | 1 | 2020 | 24 | 0.050 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 88 | 0.050 |
Why?
| | Gene Ontology | 1 | 2020 | 40 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 347 | 0.050 |
Why?
| | Chimera | 1 | 2019 | 60 | 0.050 |
Why?
| | Drug Monitoring | 2 | 2016 | 189 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 185 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2021 | 488 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1600 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2019 | 62 | 0.050 |
Why?
| | Meat | 1 | 2019 | 67 | 0.050 |
Why?
| | Prosthesis-Related Infections | 1 | 2019 | 70 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 97 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 206 | 0.040 |
Why?
| | Ribosomal Proteins | 1 | 2018 | 90 | 0.040 |
Why?
| | Population Surveillance | 1 | 2002 | 440 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1315 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3208 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 72 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 126 | 0.040 |
Why?
| | Animals, Zoo | 1 | 2017 | 10 | 0.040 |
Why?
| | Methyltransferases | 1 | 2017 | 63 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 176 | 0.040 |
Why?
| | Otitis | 1 | 2016 | 3 | 0.040 |
Why?
| | Gene Expression | 2 | 2016 | 1524 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 884 | 0.040 |
Why?
| | Pseudomonas | 1 | 2016 | 27 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2017 | 141 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2016 | 63 | 0.040 |
Why?
| | Micronesia | 1 | 2016 | 3 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2016 | 8 | 0.040 |
Why?
| | Vital Capacity | 1 | 2016 | 249 | 0.040 |
Why?
| | Spirometry | 1 | 2016 | 288 | 0.040 |
Why?
| | Needs Assessment | 1 | 2018 | 343 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 98 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 315 | 0.040 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2016 | 22 | 0.040 |
Why?
| | Drug Combinations | 1 | 2016 | 303 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2016 | 241 | 0.040 |
Why?
| | Bronchi | 1 | 2017 | 238 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 279 | 0.040 |
Why?
| | Rhinitis | 1 | 2016 | 121 | 0.040 |
Why?
| | Uganda | 1 | 2015 | 82 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 489 | 0.040 |
Why?
| | Fibrosis | 1 | 2017 | 412 | 0.040 |
Why?
| | Sinusitis | 1 | 2016 | 164 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 938 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 263 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2016 | 227 | 0.030 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2013 | 166 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 124 | 0.030 |
Why?
| | Mycobacterium avium | 1 | 2013 | 19 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2015 | 2830 | 0.030 |
Why?
| | Greece | 1 | 2012 | 4 | 0.030 |
Why?
| | DNA, Ribosomal Spacer | 1 | 2012 | 6 | 0.030 |
Why?
| | Mycolic Acids | 1 | 2012 | 8 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 713 | 0.030 |
Why?
| | Sweden | 1 | 2012 | 60 | 0.030 |
Why?
| | Bacterial Typing Techniques | 1 | 2012 | 39 | 0.030 |
Why?
| | Italy | 1 | 2012 | 94 | 0.030 |
Why?
| | Geography | 1 | 2013 | 186 | 0.030 |
Why?
| | Iran | 1 | 2012 | 68 | 0.030 |
Why?
| | Developing Countries | 2 | 2005 | 249 | 0.030 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2012 | 61 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 99 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 142 | 0.030 |
Why?
| | Protein Array Analysis | 1 | 2011 | 63 | 0.030 |
Why?
| | Microspheres | 1 | 2011 | 106 | 0.030 |
Why?
| | Species Specificity | 1 | 2013 | 617 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2016 | 648 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2014 | 290 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 295 | 0.030 |
Why?
| | Drug Discovery | 1 | 2012 | 133 | 0.030 |
Why?
| | Body Mass Index | 1 | 2019 | 2052 | 0.030 |
Why?
| | African Americans | 1 | 2016 | 963 | 0.030 |
Why?
| | Demography | 1 | 2011 | 285 | 0.030 |
Why?
| | Postoperative Care | 1 | 2012 | 237 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2015 | 529 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2014 | 416 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2012 | 473 | 0.030 |
Why?
| | Hepatitis, Chronic | 1 | 2009 | 5 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1229 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 818 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 4408 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 339 | 0.020 |
Why?
| | Pleural Diseases | 1 | 2009 | 22 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 396 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 390 | 0.020 |
Why?
| | Fatty Acids | 1 | 2012 | 429 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2009 | 130 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 479 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1584 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1460 | 0.020 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 390 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 67 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1186 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 61 | 0.020 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 17 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 264 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 3011 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 280 | 0.020 |
Why?
| | Bone Diseases | 1 | 2007 | 52 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2006 | 16 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2666 | 0.020 |
Why?
| | Africa | 1 | 2006 | 81 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 99 | 0.020 |
Why?
| | Infection Control | 1 | 2007 | 137 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2007 | 349 | 0.020 |
Why?
| | India | 1 | 2005 | 127 | 0.020 |
Why?
| | Skin Diseases | 1 | 2007 | 152 | 0.020 |
Why?
| | Virus Latency | 1 | 2005 | 89 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2012 | 892 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 223 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 942 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2007 | 488 | 0.020 |
Why?
| | Asthma | 1 | 2016 | 2039 | 0.020 |
Why?
| | Cost Savings | 1 | 2004 | 84 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2009 | 657 | 0.020 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2003 | 5 | 0.020 |
Why?
| | Pleura | 1 | 2003 | 23 | 0.020 |
Why?
| | HIV Seronegativity | 1 | 2003 | 27 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 206 | 0.020 |
Why?
| | Pleural Effusion | 1 | 2003 | 51 | 0.020 |
Why?
| | Infant | 1 | 2016 | 8096 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 112 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5137 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3828 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1675 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2847 | 0.010 |
Why?
| | Rural Population | 1 | 2005 | 467 | 0.010 |
Why?
| | Clinical Protocols | 1 | 2003 | 246 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2003 | 577 | 0.010 |
Why?
| | Health Policy | 1 | 2004 | 361 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2004 | 554 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 336 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2004 | 613 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1832 | 0.010 |
Why?
|
|
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|